Follow
William Oh
William Oh
Chief Medical Officer, Prostate Cancer Foundation; Clinical Professor of Medicine, Mount Sinai
Verified email at pcf.org - Homepage
Title
Cited by
Cited by
Year
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
22622009
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
11401999
Treatment of muscle‐invasive and advanced bladder cancer in 2020
VG Patel, WK Oh, MD Galsky
CA: a cancer journal for clinicians 70 (5), 404-423, 2020
6222020
Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy
MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ...
Journal of Clinical Oncology 29 (17), 2432-2438, 2011
6082011
PC3 is a cell line characteristic of prostatic small cell carcinoma
S Tai, Y Sun, JM Squires, H Zhang, WK Oh, CZ Liang, J Huang
The Prostate 71 (15), 1668-1679, 2011
5882011
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
E Mueller, M Smith, P Sarraf, T Kroll, A Aiyer, DS Kaufman, W Oh, ...
Proceedings of the National Academy of Sciences 97 (20), 10990-10995, 2000
5542000
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
5192018
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3762015
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
JP Eder, PW Kantoff, K Roper, GX Xu, GJ Bubley, J Boyden, L Gritz, ...
Clinical Cancer Research 6 (5), 1632-1638, 2000
3692000
Management of hormone refractory prostate cancer: current standards and future prospects
WK OH, PW KANTOFF
The Journal of urology 160 (4), 1220-1229, 1998
3641998
Consensus report: definition and interpretation of remission in type 2 diabetes
MC Riddle, WT Cefalu, PH Evans, HC Gerstein, MA Nauck, WK Oh, ...
The Journal of Clinical Endocrinology & Metabolism 107 (1), 1-9, 2022
3562022
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
3552020
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ...
The lancet oncology 12 (3), 211-214, 2011
3322011
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
D Kaufman, D Raghavan, M Carducci, EG Levine, B Murphy, J Aisner, ...
Journal of Clinical Oncology 18 (9), 1921-1927, 2000
3292000
Castration-resistant prostate cancer: AUA Guideline
MS Cookson, BJ Roth, P Dahm, C Engstrom, SJ Freedland, M Hussain, ...
The Journal of urology 190 (2), 429-438, 2013
3172013
Functional enhancers at the gene-poor 8q24 cancer-linked locus
L Jia, G Landan, M Pomerantz, R Jaschek, P Herman, D Reich, C Yan, ...
PLoS genetics 5 (8), e1000597, 2009
2922009
The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer
MM Pomerantz, S Spisák, L Jia, AM Cronin, I Csabai, E Ledet, AO Sartor, ...
Cancer 123 (18), 3532-3539, 2017
2772017
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
MD Galsky, GJ Chen, WK Oh, J Bellmunt, BJ Roth, R Petrioli, L Dogliotti, ...
Annals of oncology 23 (2), 406-410, 2012
2702012
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis
S Seng, Z Liu, SK Chiu, T Proverbs-Singh, G Sonpavde, TK Choueiri, ...
Journal of clinical oncology 30 (35), 4416-4426, 2012
2652012
EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
L Wang, A Saci, PM Szabo, SD Chasalow, M Castillo-Martin, ...
Nature communications 9 (1), 3503, 2018
2542018
The system can't perform the operation now. Try again later.
Articles 1–20